Sakar Healthcare Limited
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products
What Sakar files
- Others33
- Updates18
- Board Meeting16
- Investor Meet15
- Important15
- Results4
SAKAR HEALTHCARE affirmed proper handling of all dematerialized shares. Shares received for electronic conversion were promptly processed, confirmed with depositories, and listed on exchanges, ensuring updated investor records.
Sakar Healthcare has significantly expanded its EU market reach, securing two new Marketing Authorizations (MAs) for oncology injections, taking its total to four. These approvals for Carboplatin and Docetaxel broaden its anti-cancer portfolio for treating ovarian, lung, and other solid tumors. This strategic move paves the way for wider exports...
Sakar Healthcare has announced a board meeting to review the financial results for the quarter and half-year. The company’s Registrar and Share Transfer Agent confirmed smooth processing of share dematerialisation during the quarter, with all securities duly listed and ownership records updated. No operational changes, new orders, or financial impacts...
Sakar has announced a board meeting. The company secured its second EU Marketing Authorization for an oncology injection targeting colorectal cancer, expanding its portfolio from breast, lung, and prostate cancer treatments. This approval paves the way for boosted exports and commercialization in Europe from its integrated oncology manufacturing unit. Several...
Sakar Healthcare Limited has secured its first Marketing Authorization (MA) for an oncology injection product in the European Union, marking a significant milestone in its research-driven initiatives. This approval was achieved through a comprehensive dossier compiled under EU guidelines, validating the company's efforts in the oncology sector. The authorization paves...